Heyam Saad Ali has completed her PhD from Bradford University, UK. She is Head of Pharmaceutics Department, Dubai Pharmacy College, UAE. She has teaching and research experience of about 25 years. She has published more than 44 papers in reputed journals and has been serving as an editorial board member of several pharmaceutical Journals. She is a member of various pharmaceutical associations. In addition to attending more than 40 training courses, conferences and seminars in Quality Assurance systems. Prof. Heyam 's expertise ranges from Preformulation, Product formulation, product testing and Stability, Quality Control, Assurance and GMP processes, validation in Pharmaceutical development of conventional dosage forms.
Every woman all over the world is obsessed to attain beauty an all ages in her life. However, the health implications that may result from the chronic use of toxic additives present in cosmetic products, urge the consumer to go for herbal cosmetic products. Therefore, the aim of this study to develop and evaluate the beneficial effects of rose hip oil (ROP) topical formulation in the suitable cream. Therefore, the aim of this study to develop and evaluate the beneficial effects of rose hip oil. “Rosa mosqueta” or “Rosehip”, is a generic name which covers about 70 different species of plants of the genus Rosa, as Rosa rubiginosa, Rosa moschata and Rosa canina. In the cosmetic field, the RHO has been used for decades due to transretinoic acid or natural tretinoin (between 0.01% and 0.1%). The emollient properties of the oil has been attributed to its high content of essential fatty and unsaturated acids, polyunsaturated fatty acid highlights: linoleic acid (54%), linolenic acid (17%) and oleic acid (16%). The method involves 1- preparation of Rose hip oil (ROP) (1%) in different different concentrations (0.5,1.0, and1.5)%. 2- The evaluations of all formulations (F1 to F3) were done on different parameters like pH, Viscosity, good consistency, homogeneity, appearance spreadibilty and stability. All formulations shows no redness, edema, inflammation and irritation during irritancy. However, formulation F3 was slightly better than the other formulations in the extent of photo protection, permeability and moisturizing abilities. Rose hip oil (ROP) in 1% formulations were efficient, stable and safe to use for skin as a multipurpose cosmetic product in skin hydration, sun protection, anti-aging and rejuvenating product. According to the findings this study is promising to further clinical studies.
Dima Almutrafi is working in department of Oral Medicine & Diagnostic Sciences, division of Oral medicine, Dental College, King Saud University, Saudi Arabia
Objectives: Many treatment modalities of Myofascial Pain exist; recent literature findings suggest the superiority of use of local anesthetics as a treatment of choice. The objective of this study is to compare the effectiveness of two of the most used local anesthetic agents: Lidocaine and Mepivacaine in the management of Myofascial Pain. Materials and Methods: A total of thirty patients, 20 females and 10 males, were assigned randomly. 50% of patients received Lidocaine and 50% received Mepivacaine. Trigger points injection in the orofacial region were given 4 time, 10 days between each injection, and 4 weeks follow up after the end of the treatment course. Pain levels were recorded on Visual Analogue Scale at the time of follow-ups, and half an hour after injection. Results: All groups, total of 30 patients, 20 females and 10 males (N=30), showed statistically significant improvements when comparing the pre and post treatment means. Both types of local anesthetics, Lidocaine and Mepivacaine, were equally effective for the management of Myofascial Pain, (p = 0.875). Mepivacaine treated group showed significantly less post injection tenderness compared to Lidocaine (p = 0.038). There was no relation between gender and treatment response. Both female and male patients reported similar response VAS scores (p = 0.818) Conclusion: No drug was superior to the other on the long term, thus the clinician choice is determined by drug availability and patient medical history.